Cargando…

Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease

Background: The long-term intermittent Levodopa (L-dopa) stimulation contributes to an aberrant activation of D1 receptor (D1R) mediated extracellular signal-regulated kinases1/2 (ERK1/2) in the striatal medium spiny neurons, resulting in the occurrence of L-dopa induced dyskinesia (LID). Recently,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wan, Ying, Wu, Na, Song, Lu, Wang, Xijin, Liu, Zhenguo, Yuan, Weien, Gan, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651254/ https://www.ncbi.nlm.nih.gov/pubmed/29093677 http://dx.doi.org/10.3389/fnagi.2017.00331

Ejemplares similares

Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats
por: Yang, Xinxin, et al.
Publicado: (2012)

Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats
por: Yang, Xinxin, et al.
Publicado: (2012)

Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa–Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson’s Rats
por: Wang, Wen-Wen, et al.
Publicado: (2019)

Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats
por: Xie, Cheng-long, et al.
Publicado: (2014)

The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Wu, Na, et al.
Publicado: (2018)

Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC/MEK/ERK Pathway
por: Yan, Aijuan, et al.
Publicado: (2021)

Effect of L-DOPA/Benserazide on Propagation of Pathological α-Synuclein
por: Shimozawa, Aki, et al.
Publicado: (2019)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
por: Zheng, Chang-Qing, et al.
Publicado: (2021)

Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease
por: Teng, Long, et al.
Publicado: (2014)

Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®
por: Gasser, Urs E, et al.
Publicado: (2013)

Betaine protects cerebellum from oxidative stress following levodopa and benserazide administration in rats
por: Alirezaei, Masoud
Publicado: (2015)

Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson’s disease
por: Yang, Yifan, et al.
Publicado: (2023)

Esophageal Atresia in a Newborn Born to a Parkinson's Mother Had L-Dopa/Benserazide Treatment during Pregnancy
por: Hamamcı, Mehmet, et al.
Publicado: (2019)

β-arrestin2 alleviates L-dopa–induced dyskinesia via lower D1R activity in Parkinson’s rats
por: Zhang, Xing-Ru, et al.
Publicado: (2019)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

3D Printed Mini-Floating-Polypill for Parkinson’s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy
por: Windolf, Hellen, et al.
Publicado: (2022)

Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease
por: Athulya, RT, et al.
Publicado: (2020)

Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias
por: Gan, Caiting, et al.
Publicado: (2020)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas, Panagiotis, et al.
Publicado: (2013)

Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Cerasa, Antonio, et al.
Publicado: (2015)

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
por: Krishnan, Syam, et al.
Publicado: (2017)

Cerebellar connectivity in Parkinson's disease with levodopa‐induced dyskinesia
por: Yoo, Han Soo, et al.
Publicado: (2019)

Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson’s disease
por: Yang, Xinxin, et al.
Publicado: (2013)

Electroanalytical Overview: The Determination of Levodopa (L-DOPA)
por: Crapnell, Robert D., et al.
Publicado: (2023)

Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats
por: Zhang, SuFang, et al.
Publicado: (2014)

Targeting the D1-N-methyl-d-aspartate receptor complex reduces l-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Song, Lu, et al.
Publicado: (2016)

LOW DOSE LEVODOPA IN TARDIVE DYSKINESIA
por: Sethi, Sujata, et al.
Publicado: (1990)

Involvement of Autophagy in Levodopa‐Induced Dyskinesia
por: Feyder, Michael, et al.
Publicado: (2021)

Altered dynamic functional network connectivity in levodopa‐induced dyskinesia of Parkinson's disease
por: Si, Qianqian, et al.
Publicado: (2022)

Electrochemical Sensor Based on Multi-Walled Carbon Nanotubes and N-Doped TiO(2) Nanoparticles for Voltametric Simultaneous Determination of Benserazide and Levodopa
por: da Silva, Elisangela Pacheco, et al.
Publicado: (2022)

Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson’s disease mouse model
por: Doo, Ah-Reum, et al.
Publicado: (2014)

The acute brain response to levodopa heralds dyskinesias in Parkinson disease
por: Herz, Damian M., et al.
Publicado: (2014)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Opioid system in L-DOPA-induced dyskinesia
por: Pan, Jing, et al.
Publicado: (2017)

Dopamine pathway and Parkinson's risk variants are associated with levodopa-induced dyskinesia
por: Sosero, Yuri L., et al.
Publicado: (2023)

Transcranial Magnetic Stimulation Alleviates Levodopa-Induced Dyskinesia in Parkinson's Disease and the Related Mechanisms: A Mini-Review
por: Wu, Yi, et al.
Publicado: (2021)

Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonism
por: Baufreton, Jérôme, et al.
Publicado: (2018)

Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia
por: Bido, Simone, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hu2dfvin52spa42naho698n3op